MALVERN, PA — Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings, Inc. and an industry leader in cancer biomarker assays, announced that Cigna has added ROMA® (Risk of Ovarian Malignancy Algorithm) to its national preferred coverage list.
Cigna Corporation is a global health service company dedicated to improving the health, well-being, and peace of mind of the customers they serve. This decision to add ROMA further demonstrates Cigna’s focus to help reduce patient health costs and achieve optimal health outcomes.
The ACOG (American College of Obstetricians and Gynecologists) recommendations include ROMA as one of several risk assessment algorithms when referring patients with an adnexal mass. ROMA is a qualitative test that combines the quantitative results of HE4, CA 125 and menopausal status into a numerical score.
It can be performed in any laboratory that also provides CA 125 testing services. Each ROMA result automatically includes the individual results of CA 125, HE4 and the ROMA score.
ROMA is intended to aid in assessing whether premenopausal or postmenopausal women who present with an ovarian adnexal mass are at high or low likelihood of finding malignancy on surgery.
CA 125 is within normal limits in 50% of women with stage 1 disease, is often falsely positive in benign conditions like endometriosis, and is not approved as a risk assessment tool for ovarian masses. ROMA helps to address some of these shortcomings.
“With over 21,000 women in the U.S. diagnosed per year with ovarian cancer, we are pleased to see the increase in the number of women who will now have access to ROMA,” says Monte Wiltse, CEO/President at Fujirebio Diagnostics, Inc. “Early and appropriate care by a gynecologic oncologist can help increase survival rates in women with ovarian cancer and decrease the number of complications.”
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.